Histological and histomorphometrical analysis of a silica matrix embedded nanocrystalline hydroxyapatite bone substitute using the subcutaneous implantation model in Wistar rats.
The clinical suitability of a bone substitute material is determined by the ability to induce a tissue reaction specific to its composition. The aim of this in vivo study was to analyze the tissue reaction to a silica matrix-embedded, nanocrystalline hydroxyapatite bone substitute.The subcutaneous implantation model in Wistar rats was chosen to assess the effect of silica degradation on the vascularization of the biomaterial and its biodegradation within a time period of 6 months. Already at day 10 after implantation, histomorphometrical analysis showed that the vascularization of the implantation bed reached its peak value compared to all other time points. Both vessel density and vascularization significantly decreased until day 90 after implantation. In this time period, the bone substitute underwent a significant degradation initiated by TRAP-positive and TRAP-negative multinucleated giant cells together with macrophages and lymphocytes. Although no specific tissue reaction could be related to the described silica degradation, the biomaterial was close to being fully degraded without a severe inflammatory response. These characteristics are advantageous for bone regeneration and remodeling processes.
Ghanaati
Shahram
S
Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße 1, 55101 Mainz, Germany; Department for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Medical Center of the Goethe University Frankfurt, Theodor-Stein-Kai 7, 60596 Frankfurt am Main, Germany.  ghanaati@uni-mainz.de
Orth
Carina
C
Barbeck
Mike
M
Willershausen
Ines
I
Thimm
Benjamin W
BW
Booms
Patrick
P
Stübinger
Stefan
S
Landes
Constantin
C
Sader
Robert Anton
RA
Kirkpatrick
Charles James
CJ
D020341:Absorbable Implants; D000818:Animals; D018786:Bone Substitutes / Q000008:administration & dosage* / Q000737:chemistry; D004338:Drug Combinations; D017886:Durapatite / Q000008:administration & dosage / Q000737:chemistry*; D005260:Female; D008422:Materials Testing; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D012822:Silicon Dioxide / Q000008:administration & dosage* / Q000737:chemistry; D040521:Subcutaneous Tissue / Q000187:drug effects* / Q000473:pathology*
D018786:Bone Substitutes; D004338:Drug Combinations; C534915:NanoBone; D012822:Silicon Dioxide; D017886:Durapatite